BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sanchez C, Asin KE, Artigas F. Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. Pharmacology & Therapeutics 2015;145:43-57. [DOI: 10.1016/j.pharmthera.2014.07.001] [Cited by in Crossref: 245] [Cited by in F6Publishing: 200] [Article Influence: 40.8] [Reference Citation Analysis]
Number Citing Articles
1 Wang D, Xu X, Wu Y, Lin Y, Gao M, Hu P, Chen D, Lu X, Chen Z, Wang H, Huang C. SMIP004: A compound with antidepressant-like activities in mouse models. European Journal of Pharmacology 2019;843:260-7. [DOI: 10.1016/j.ejphar.2018.11.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Sobreira G, Oliveira J, Brissos S. Vortioxetine-induced manic mood switch in patient with previously unknown bipolar disorder. Braz J Psychiatry 2017;39:86. [PMID: 28273272 DOI: 10.1590/1516-4446-2016-2113] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Christensen MC, Loft H, Mcintyre RS. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders. Journal of Affective Disorders 2018;227:787-94. [DOI: 10.1016/j.jad.2017.11.081] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
4 Mills NT, Sampson E, Fourrier C, Baune BT. Clinical Switching Strategies of Various Antidepressants to Vortioxetine in the PREDDICT Trial. Int J Neuropsychopharmacol 2021;24:314-21. [PMID: 33269395 DOI: 10.1093/ijnp/pyaa092] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Sowa-kućma M, Pańczyszyn-trzewik P, Misztak P, Jaeschke RR, Sendek K, Styczeń K, Datka W, Koperny M. Vortioxetine: A review of the pharmacology and clinical profile of the novel antidepressant. Pharmacological Reports 2017;69:595-601. [DOI: 10.1016/j.pharep.2017.01.030] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
6 Köhler S, Cierpinsky K, Kronenberg G, Adli M. The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants. J Psychopharmacol 2016;30:13-22. [DOI: 10.1177/0269881115609072] [Cited by in Crossref: 73] [Cited by in F6Publishing: 61] [Article Influence: 14.6] [Reference Citation Analysis]
7 Riga MS, Teruel-martí V, Sánchez C, Celada P, Artigas F. Subchronic vortioxetine treatment –but not escitalopram– enhances pyramidal neuron activity in the rat prefrontal cortex. Neuropharmacology 2017;113:148-55. [DOI: 10.1016/j.neuropharm.2016.09.024] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
8 Baune BT, Brignone M, Larsen KG. A Network Meta-Analysis Comparing Effects of Various Antidepressant Classes on the Digit Symbol Substitution Test (DSST) as a Measure of Cognitive Dysfunction in Patients with Major Depressive Disorder. Int J Neuropsychopharmacol 2018;21:97-107. [PMID: 29053849 DOI: 10.1093/ijnp/pyx070] [Cited by in Crossref: 47] [Cited by in F6Publishing: 36] [Article Influence: 23.5] [Reference Citation Analysis]
9 Perini G, Cotta Ramusino M, Sinforiani E, Bernini S, Petrachi R, Costa A. Cognitive impairment in depression: recent advances and novel treatments. Neuropsychiatr Dis Treat 2019;15:1249-58. [PMID: 31190831 DOI: 10.2147/NDT.S199746] [Cited by in Crossref: 42] [Cited by in F6Publishing: 13] [Article Influence: 21.0] [Reference Citation Analysis]
10 Wilson S, Højer AM, Buchberg J, Areberg J, Nutt DJ. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. J Psychopharmacol 2015;29:1085-91. [PMID: 26253622 DOI: 10.1177/0269881115599387] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
11 Keks NA, Hope J, Culhane C. Vortioxetine: A multimodal antidepressant or another selective serotonin reuptake inhibitor? Australas Psychiatry 2015;23:210-3. [DOI: 10.1177/1039856215581297] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
12 Bennabi D, Haffen E, Van Waes V. Vortioxetine for Cognitive Enhancement in Major Depression: From Animal Models to Clinical Research. Front Psychiatry 2019;10:771. [PMID: 31780961 DOI: 10.3389/fpsyt.2019.00771] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
13 Dawson GR. Experimental Medicine in Psychiatry New Approaches in Schizophrenia, Depression and Cognition. In: Robbins TW, Sahakian BJ, editors. Translational Neuropsychopharmacology. Cham: Springer International Publishing; 2016. pp. 475-97. [DOI: 10.1007/7854_2015_5016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Mahableshwarkar AR, Affinito J, Reines EH, Xu J, Nomikos G, Jacobsen PL. Suicidal ideation and behavior in adults with major depressive disorder treated with vortioxetine: post hoc pooled analyses of randomized, placebo-controlled, short-term and open-label, long-term extension trials. CNS Spectr 2020;25:352-62. [PMID: 31199210 DOI: 10.1017/S109285291900097X] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
15 Yücel NT, Osmaniye D, Kandemir Ü, Evren AE, Can ÖD, Demir Özkay Ü. Synthesis and Antinociceptive Effect of Some Thiazole-Piperazine Derivatives: Involvement of Opioidergic System in the Activity. Molecules 2021;26:3350. [PMID: 34199486 DOI: 10.3390/molecules26113350] [Reference Citation Analysis]
16 Ślifirski G, Król M, Kleps J, Ulenberg S, Belka M, Bączek T, Siwek A, Stachowicz K, Szewczyk B, Nowak G, Bojarski A, Kozioł AE, Turło J, Herold F. Synthesis of novel pyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands. Eur J Med Chem 2019;166:144-58. [PMID: 30703658 DOI: 10.1016/j.ejmech.2019.01.031] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
17 Moreira LKDS, de Brito AF, da Silva DM, Siqueira L, da Silva DPB, Cardoso CS, Florentino IF, de Carvalho PMG, Ghedini PC, Menegatti R, Costa EA. Potential antidepressant-like effect of piperazine derivative LQFM212 in mice: Role of monoaminergic pathway and brain-derived neurotrophic factor. Behav Brain Res 2021;401:113066. [PMID: 33333109 DOI: 10.1016/j.bbr.2020.113066] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Żmudzka E, Sałaciak K, Sapa J, Pytka K. Serotonin receptors in depression and anxiety: Insights from animal studies. Life Sci 2018;210:106-24. [PMID: 30144453 DOI: 10.1016/j.lfs.2018.08.050] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 22.7] [Reference Citation Analysis]
19 Christensen MC, Florea I, Loft H, McIntyre RS. Efficacy of vortioxetine in patients with major depressive disorder reporting childhood or recent trauma. J Affect Disord 2020;263:258-66. [PMID: 31818787 DOI: 10.1016/j.jad.2019.11.074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Martis LS, Højgaard K, Holmes MC, Elfving B, Wiborg O. Vortioxetine ameliorates anhedonic-like behaviour and promotes strategic cognitive performance in a rodent touchscreen task. Sci Rep 2021;11:9113. [PMID: 33907240 DOI: 10.1038/s41598-021-88462-7] [Reference Citation Analysis]
21 Inoue T, Nishimura A, Sasai K, Kitagawa T. Randomized, 8-week, double-blind, placebo-controlled trial of vortioxetine in Japanese adults with major depressive disorder, followed by a 52-week open-label extension trial: Vortioxetine in Japanese MDD patients. Psychiatry Clin Neurosci 2018;72:103-15. [DOI: 10.1111/pcn.12623] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
22 Gulinello M, Mitchell HA, Chang Q, Timothy O'Brien W, Zhou Z, Abel T, Wang L, Corbin JG, Veeraragavan S, Samaco RC, Andrews NA, Fagiolini M, Cole TB, Burbacher TM, Crawley JN. Rigor and reproducibility in rodent behavioral research. Neurobiol Learn Mem 2019;165:106780. [PMID: 29307548 DOI: 10.1016/j.nlm.2018.01.001] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 7.7] [Reference Citation Analysis]
23 Santana N, Artigas F. Expression of Serotonin 2C Receptors in Pyramidal and GABAergic Neurons of Rat Prefrontal Cortex: A Comparison with Striatum. Cereb Cortex. [DOI: 10.1093/cercor/bhw148] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
24 du Jardin KG, Müller HK, Sanchez C, Wegener G, Elfving B. A single dose of vortioxetine, but not ketamine or fluoxetine, increases plasticity-related gene expression in the rat frontal cortex. Eur J Pharmacol 2016;786:29-35. [PMID: 27235984 DOI: 10.1016/j.ejphar.2016.05.029] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
25 Laursen B, Bundgaard CH, Graversen C, Grupe M, Sanchez C, Leiser SC, Sorensen HB, Drewes AM, Bastlund JF. Acute dosing of vortioxetine strengthens event-related brain activity associated with engagement of attention and cognitive functioning in rats. Brain Research 2017;1664:37-47. [DOI: 10.1016/j.brainres.2017.03.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Christensen MC, Loft H, Florea I, McIntyre RS. Efficacy of vortioxetine in working patients with generalized anxiety disorder. CNS Spectr 2019;24:249-57. [PMID: 29081307 DOI: 10.1017/S1092852917000761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
27 du Jardin KG, Liebenberg N, Müller HK, Elfving B, Sanchez C, Wegener G. Differential interaction with the serotonin system by S-ketamine, vortioxetine, and fluoxetine in a genetic rat model of depression. Psychopharmacology (Berl) 2016;233:2813-25. [PMID: 27236785 DOI: 10.1007/s00213-016-4327-5] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
28 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): blocking 5HT3 receptors enhances release of serotonin, norepinephrine, and acetylcholine. CNS Spectr 2015;20:455-9. [DOI: 10.1017/s1092852915000346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
29 Delcourte S, Etievant A, Haddjeri N. Role of central serotonin and noradrenaline interactions in the antidepressants' action: Electrophysiological and neurochemical evidence. Prog Brain Res 2021;259:7-81. [PMID: 33541681 DOI: 10.1016/bs.pbr.2021.01.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Hatherall L, Sánchez C, Morilak DA. Chronic Vortioxetine Treatment Reduces Exaggerated Expression of Conditioned Fear Memory and Restores Active Coping Behavior in Chronically Stressed Rats. Int J Neuropsychopharmacol 2017;20:316-23. [PMID: 27927740 DOI: 10.1093/ijnp/pyw105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
31 Yang YK, Chen CS, Tsai CF, Chang CM, Lai TJ, Lee CT, Lin CC, Lan TH, Herr KJ. A Taiwanese study on real-world evidence with vortioxetine in patients with major depression in Asia (TREVIDA). Curr Med Res Opin 2021;:1-11. [PMID: 34515596 DOI: 10.1080/03007995.2021.1980869] [Reference Citation Analysis]
32 Taylor WD, Schultz SK, Panaite V, Steffens DC. Perspectives on the Management of Vascular Depression. Am J Psychiatry 2018;175:1169-75. [PMID: 30501416 DOI: 10.1176/appi.ajp.2018.18050568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Lowe P, Krivoy A, Porffy L, Henriksdottir E, Eromona W, Shergill SS. When the drugs don't work: treatment-resistant schizophrenia, serotonin and serendipity. Ther Adv Psychopharmacol 2018;8:63-70. [PMID: 29344345 DOI: 10.1177/2045125317737003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
34 Smith J, Browning M, Conen S, Smallman R, Buchbjerg J, Larsen KG, Olsen CK, Christensen SR, Dawson GR, Deakin JF, Hawkins P, Morris R, Goodwin G, Harmer CJ. Vortioxetine reduces BOLD signal during performance of the N-back working memory task: a randomised neuroimaging trial in remitted depressed patients and healthy controls. Mol Psychiatry 2018;23:1127-33. [PMID: 28533517 DOI: 10.1038/mp.2017.104] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 7.0] [Reference Citation Analysis]
35 Jacobsen P, Zhong W, Nomikos G, Clayton A. Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. J Sex Med 2019;16:1638-49. [PMID: 31405765 DOI: 10.1016/j.jsxm.2019.06.018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
36 Rahimian R, Fakhfouri G, Zirak MR. Pros and cons of 5-HT3 receptor antagonists in neuropsychiatric diseases. Biomed Pharmacother 2019;118:109301. [PMID: 31402188 DOI: 10.1016/j.biopha.2019.109301] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Yi Y, Ren G, Zheng M, Zhao D, Li N, Chen X, Lu Y. Simultaneous determination of deuterated vortioxetine and its major metabolite in human plasma by UPLC-MS/MS and application to a pharmacokinetic study in healthy volunteers. Journal of Chromatography B 2020;1138:121955. [DOI: 10.1016/j.jchromb.2019.121955] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Levada OA, Troyan AS. Cognitive-functional relationships in major depressive disorder: Crucial data from a Ukrainian open-label study of vortioxetine versus escitalopram. Journal of Affective Disorders 2019;250:114-22. [DOI: 10.1016/j.jad.2019.03.040] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
39 Ebada ME. Drug repurposing may generate novel approaches to treating depression. Journal of Pharmacy and Pharmacology 2017;69:1428-36. [DOI: 10.1111/jphp.12815] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
40 Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M, Trivedi MH. A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl) 2015;232:2061-70. [PMID: 25575488 DOI: 10.1007/s00213-014-3839-0] [Cited by in Crossref: 56] [Cited by in F6Publishing: 45] [Article Influence: 9.3] [Reference Citation Analysis]
41 Waller JA, Tamm JA, Abdourahman A, Pehrson AL, Li Y, Cajina M, Sánchez C. Chronic vortioxetine treatment in rodents modulates gene expression of neurodevelopmental and plasticity markers. Eur Neuropsychopharmacol 2017;27:192-203. [PMID: 28108062 DOI: 10.1016/j.euroneuro.2016.11.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
42 Palazidou E. Traditional and Novel Possible Targets for Antidepressant Drugs. In: Grosso C, editor. Herbal Medicine in Depression. Cham: Springer International Publishing; 2016. pp. 43-73. [DOI: 10.1007/978-3-319-14021-6_2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
43 Papakostas GI, Ionescu DF. Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry 2015;20:1142-50. [PMID: 26148812 DOI: 10.1038/mp.2015.92] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 11.3] [Reference Citation Analysis]
44 Liu F, Wu J, Gong Y, Wang P, Zhu L, Tong L, Chen X, Ling Y, Huang C. Harmine produces antidepressant-like effects via restoration of astrocytic functions. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2017;79:258-67. [DOI: 10.1016/j.pnpbp.2017.06.012] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
45 Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Serretti A. Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis. J Psychiatr Res 2015;64:88-98. [PMID: 25851751 DOI: 10.1016/j.jpsychires.2015.02.017] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
46 Santana N, Artigas F. Laminar and Cellular Distribution of Monoamine Receptors in Rat Medial Prefrontal Cortex. Front Neuroanat 2017;11:87. [PMID: 29033796 DOI: 10.3389/fnana.2017.00087] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 11.8] [Reference Citation Analysis]
47 Zimmerman M, Clark HL, Multach MD, Walsh E, Rosenstein LK, Gazarian D. Inclusion/exclusion criteria in placebo-controlled studies of vortioxetine: Comparison to other antidepressants and implications for product labeling. J Affect Disord 2016;190:357-61. [PMID: 26546771 DOI: 10.1016/j.jad.2015.10.041] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
48 Di Giovanni G, Svob Strac D, Sole M, Unzeta M, Tipton KF, Mück-Šeler D, Bolea I, Della Corte L, Nikolac Perkovic M, Pivac N, Smolders IJ, Stasiak A, Fogel WA, De Deurwaerdère P. Monoaminergic and Histaminergic Strategies and Treatments in Brain Diseases. Front Neurosci 2016;10:541. [PMID: 27932945 DOI: 10.3389/fnins.2016.00541] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
49 Talmon M, Rossi S, Pastore A, Cattaneo CI, Brunelleschi S, Fresu LG. Vortioxetine exerts anti-inflammatory and immunomodulatory effects on human monocytes/macrophages. Br J Pharmacol 2018;175:113-24. [PMID: 29057467 DOI: 10.1111/bph.14074] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 5.8] [Reference Citation Analysis]
50 McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat 2017;13:2913-9. [PMID: 29238196 DOI: 10.2147/NDT.S150589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
51 Podkowa K, Pilc A, Podkowa A, Sałat K, Marciniak M, Pałucha-Poniewiera A. The potential antidepressant action and adverse effects profile of scopolamine co-administered with the mGlu7 receptor allosteric agonist AMN082 in mice. Neuropharmacology 2018;141:214-22. [PMID: 30145321 DOI: 10.1016/j.neuropharm.2018.08.022] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
52 Nishimura A, Aritomi Y, Sasai K, Kitagawa T, Mahableshwarkar AR. Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder: Vortioxetine for major depression. Psychiatry Clin Neurosci 2018;72:64-72. [DOI: 10.1111/pcn.12565] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
53 Riga MS, Sanchez C, Celada P, Artigas F. Sub-chronic vortioxetine (but not escitalopram) normalizes brain rhythm alterations and memory deficits induced by serotonin depletion in rats. Neuropharmacology 2020;178:108238. [DOI: 10.1016/j.neuropharm.2020.108238] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Franklin M, Hlavacova N, Li Y, Bermudez I, Csanova A, Sanchez C, Jezova D. Reprint of: Contrasting effects of vortioxetine and paroxetine on pineal gland biochemistry in a tryptophan-depletion model of depression in female rats. Prog Neuropsychopharmacol Biol Psychiatry 2018;82:339-42. [PMID: 29277417 DOI: 10.1016/j.pnpbp.2017.12.010] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
55 Li Y, Pehrson AL, Oosting RS, Gulinello M, Olivier B, Sanchez C. A study of time- and sex-dependent effects of vortioxetine on rat sexual behavior: Possible roles of direct receptor modulation. Neuropharmacology 2017;121:89-99. [DOI: 10.1016/j.neuropharm.2017.04.017] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
56 Zhou X, Hu X, Wu S, Ye J, Sun M, Gu J, Zhu J, Zhang Z. Structures and physicochemical properties of vortioxetine salts. Acta Crystallogr B Struct Sci Cryst Eng Mater 2016;72:723-32. [DOI: 10.1107/s2052520616010556] [Cited by in Crossref: 6] [Article Influence: 1.2] [Reference Citation Analysis]
57 Clayton AH, Alkis AR, Parikh NB, Votta JG. Sexual Dysfunction Due to Psychotropic Medications. Psychiatr Clin North Am 2016;39:427-63. [PMID: 27514298 DOI: 10.1016/j.psc.2016.04.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 19] [Article Influence: 6.8] [Reference Citation Analysis]
58 Deardorff WJ, Grossberg GT. The Pharmacology and Clinical Use of the Antidepressants Vilazodone, Levomilnacipran, and Vortioxetine for Depression in the Elderly. Curr Geri Rep 2015;4:301-11. [DOI: 10.1007/s13670-015-0140-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Yang Y, Zhang L, Yu J, Ma Z, Li M, Wang J, Hu P, Zou J, Liu X, Liu Y, An S, Xiang C, Guo X, Hao Q, Xu TR. A Novel 5-HT1B Receptor Agonist of Herbal Compounds and One of the Therapeutic Uses for Alzheimer's Disease. Front Pharmacol 2021;12:735876. [PMID: 34552493 DOI: 10.3389/fphar.2021.735876] [Reference Citation Analysis]
60 Zuena AR, Maftei D, Alemà GS, Dal Moro F, Lattanzi R, Casolini P, Nicoletti F. Multimodal antidepressant vortioxetine causes analgesia in a mouse model of chronic neuropathic pain. Mol Pain 2018;14:1744806918808987. [PMID: 30289053 DOI: 10.1177/1744806918808987] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
61 Thase ME, Danchenko N, Brignone M, Florea I, Diamand F, Jacobsen PL, Vieta E. Comparative evaluation of vortioxetine as a switch therapy in patients with major depressive disorder. European Neuropsychopharmacology 2017;27:773-81. [DOI: 10.1016/j.euroneuro.2017.05.009] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
62 Millan MJ, Goodwin GM, Meyer-lindenberg A, Ove Ögren S. Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. European Neuropsychopharmacology 2015;25:599-656. [DOI: 10.1016/j.euroneuro.2015.01.016] [Cited by in Crossref: 88] [Cited by in F6Publishing: 73] [Article Influence: 14.7] [Reference Citation Analysis]
63 Ragi NC, Velma GR, Pallerla PK, Siddiqua S, Alugonda V, Rachamalla HKR, Pabbaraja S, Sripadi P. Identification and characterization of forced degradation products of vortioxetine by LC/MS/MS and NMR. J Pharm Biomed Anal 2020;188:113442. [PMID: 32622114 DOI: 10.1016/j.jpba.2020.113442] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Švob Štrac D, Pivac N, Mück-Šeler D. The serotonergic system and cognitive function. Transl Neurosci 2016;7:35-49. [PMID: 28123820 DOI: 10.1515/tnsci-2016-0007] [Cited by in Crossref: 64] [Cited by in F6Publishing: 64] [Article Influence: 12.8] [Reference Citation Analysis]
65 Biederman J, Lindsten A, Sluth LB, Petersen ML, Ettrup A, Eriksen HF, Fava M. Vortioxetine for attention deficit hyperactivity disorder in adults: A randomized, double-blind, placebo-controlled, proof-of-concept study. J Psychopharmacol 2019;33:511-21. [PMID: 30843450 DOI: 10.1177/0269881119832538] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
66 Smagin GN, Song D, Budac DP, Waller JA, Li Y, Pehrson AL, Sánchez C. Histamine may contribute to vortioxetine's procognitive effects; possibly through an orexigenic mechanism. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016;68:25-30. [DOI: 10.1016/j.pnpbp.2016.03.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
67 Dale E, Zhang H, Leiser SC, Xiao Y, Lu D, Yang CR, Plath N, Sanchez C. Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. J Psychopharmacol 2014;28:891-902. [PMID: 25122043 DOI: 10.1177/0269881114543719] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 8.6] [Reference Citation Analysis]
68 Chen G, Nomikos GG, Affinito J, Zhao Z. Lack of Effect of Vortioxetine on the Pharmacokinetics and Pharmacodynamics of Ethanol, Diazepam, and Lithium. Clin Pharmacokinet 2016;55:1115-27. [PMID: 27048210 DOI: 10.1007/s40262-016-0389-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
69 Kertys M, Krivosova M, Ondrejka I, Hrtanek I, Tonhajzerova I, Mokry J. Simultaneous determination of fluoxetine, venlafaxine, vortioxetine and their active metabolites in human plasma by LC-MS/MS using one-step sample preparation procedure. J Pharm Biomed Anal 2020;181:113098. [PMID: 31978643 DOI: 10.1016/j.jpba.2020.113098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
70 Du Y, Jiang J, Ng CH, Wu L, Zhang P, Xi C, Lai J, Xu Y, Hu S, Wang Z. Vortioxetine improves rapid eye movement sleep behavior disorder: A case report. Medicine (Baltimore) 2020;99:e21003. [PMID: 32590816 DOI: 10.1097/MD.0000000000021003] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
71 Athira KV, Bandopadhyay S, Samudrala PK, Naidu VGM, Lahkar M, Chakravarty S. An Overview of the Heterogeneity of Major Depressive Disorder: Current Knowledge and Future Prospective. Curr Neuropharmacol 2020;18:168-87. [PMID: 31573890 DOI: 10.2174/1570159X17666191001142934] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
72 Frampton JE. Vortioxetine: A Review in Cognitive Dysfunction in Depression. Drugs 2016;76:1675-82. [DOI: 10.1007/s40265-016-0655-3] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
73 Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of Vortioxetine vs. Escitalopram on Sexual Functioning in Adults with Well-Treated Major Depressive Disorder Experiencing SSRI-Induced Sexual Dysfunction. J Sex Med 2015;12:2036-48. [PMID: 26331383 DOI: 10.1111/jsm.12980] [Cited by in Crossref: 45] [Cited by in F6Publishing: 27] [Article Influence: 7.5] [Reference Citation Analysis]
74 Baune BT, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. J Affect Disord 2018;229:421-8. [PMID: 29331703 DOI: 10.1016/j.jad.2017.12.056] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
75 Papakostas GI, Nielsen RZ, Dragheim M, Tonnoir B. Efficacy and tolerability of vortioxetine versus agomelatine, categorized by previous treatment, in patients with major depressive disorder switched after an inadequate response. Journal of Psychiatric Research 2018;101:72-9. [DOI: 10.1016/j.jpsychires.2018.02.017] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 3.7] [Reference Citation Analysis]
76 Chakroborty S, Geisbush TR, Dale E, Pehrson AL, Sánchez C, West AR. Impact of Vortioxetine on Synaptic Integration in Prefrontal-Subcortical Circuits: Comparisons with Escitalopram. Front Pharmacol 2017;8:764. [PMID: 29123483 DOI: 10.3389/fphar.2017.00764] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
77 Riga MS, Sánchez C, Celada P, Artigas F. Involvement of 5-HT 3 receptors in the action of vortioxetine in rat brain: Focus on glutamatergic and GABAergic neurotransmission. Neuropharmacology 2016;108:73-81. [DOI: 10.1016/j.neuropharm.2016.04.023] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 8.8] [Reference Citation Analysis]
78 Zhang Y, Ge J, Wang F, Liu F, Shi C, Li N. Crassifoside H improve the depressive-like behavior of rats under chronic unpredictable mild stress: Possible involved mechanisms. Brain Research Bulletin 2017;135:77-84. [DOI: 10.1016/j.brainresbull.2017.09.015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
79 Girotti M, Adler SM, Bulin SE, Fucich EA, Paredes D, Morilak DA. Prefrontal cortex executive processes affected by stress in health and disease. Prog Neuropsychopharmacol Biol Psychiatry 2018;85:161-79. [PMID: 28690203 DOI: 10.1016/j.pnpbp.2017.07.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 8.5] [Reference Citation Analysis]
80 du Jardin KG, Müller HK, Elfving B, Dale E, Wegener G, Sanchez C. Potential involvement of serotonergic signaling in ketamine's antidepressant actions: A critical review. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2016;71:27-38. [DOI: 10.1016/j.pnpbp.2016.05.007] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
81 Torrisi SA, Geraci F, Tropea MR, Grasso M, Caruso G, Fidilio A, Musso N, Sanfilippo G, Tascedda F, Palmeri A, Salomone S, Drago F, Puzzo D, Leggio GM, Caraci F. Fluoxetine and Vortioxetine Reverse Depressive-Like Phenotype and Memory Deficits Induced by Aβ1-42 Oligomers in Mice: A Key Role of Transforming Growth Factor-β1. Front Pharmacol 2019;10:693. [PMID: 31293421 DOI: 10.3389/fphar.2019.00693] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
82 Atique-ur-rehman H, Neill JC. Cognitive dysfunction in major depression: From assessment to novel therapies. Pharmacology & Therapeutics 2019;202:53-71. [DOI: 10.1016/j.pharmthera.2019.05.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 7.0] [Reference Citation Analysis]
83 McIntyre RS, Harrison J, Loft H, Jacobson W, Olsen CK. The Effects of Vortioxetine on Cognitive Function in Patients with Major Depressive Disorder: A Meta-Analysis of Three Randomized Controlled Trials. Int J Neuropsychopharmacol 2016;19:pyw055. [PMID: 27312740 DOI: 10.1093/ijnp/pyw055] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 16.4] [Reference Citation Analysis]
84 Farooq RK, Tanti A, Ainouche S, Roger S, Belzung C, Camus V. A P2X7 receptor antagonist reverses behavioural alterations, microglial activation and neuroendocrine dysregulation in an unpredictable chronic mild stress (UCMS) model of depression in mice. Psychoneuroendocrinology 2018;97:120-30. [DOI: 10.1016/j.psyneuen.2018.07.016] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 10.3] [Reference Citation Analysis]
85 Yang KC, Stepanov V, Amini N, Martinsson S, Takano A, Bundgaard C, Bang-Andersen B, Sanchez C, Halldin C, Farde L, Finnema SJ. Effect of clinically relevant doses of vortioxetine and citalopram on serotonergic PET markers in the nonhuman primate brain. Neuropsychopharmacology 2019;44:1706-13. [PMID: 31216565 DOI: 10.1038/s41386-019-0442-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
86 Felice D, Guilloux JP, Pehrson A, Li Y, Mendez-David I, Gardier AM, Sanchez C, David DJ. Vortioxetine Improves Context Discrimination in Mice Through a Neurogenesis Independent Mechanism. Front Pharmacol 2018;9:204. [PMID: 29593535 DOI: 10.3389/fphar.2018.00204] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
87 Leiser SC, Iglesias-Bregna D, Westrich L, Pehrson AL, Sanchez C. Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 2, pharmacological interactions in rodents suggest a role of serotonin-3 receptor antagonism. J Psychopharmacol 2015;29:1092-105. [PMID: 26174134 DOI: 10.1177/0269881115592347] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
88 Pehrson AL, Hillhouse TM, Haddjeri N, Rovera R, Porter JH, Mørk A, Smagin G, Song D, Budac D, Cajina M, Sanchez C. Task- and Treatment Length-Dependent Effects of Vortioxetine on Scopolamine-Induced Cognitive Dysfunction and Hippocampal Extracellular Acetylcholine in Rats. J Pharmacol Exp Ther 2016;358:472-82. [PMID: 27402279 DOI: 10.1124/jpet.116.233924] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
89 Christensen MC, Munro V. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome. Current Medical Research and Opinion 2018;34:593-600. [DOI: 10.1080/03007995.2017.1416952] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
90 Iderberg H, Mccreary A, Varney M, Kleven M, Koek W, Bardin L, Depoortère R, Cenci M, Newman-tancredi A. NLX-112, a novel 5-HT 1A receptor agonist for the treatment of l -DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. Experimental Neurology 2015;271:335-50. [DOI: 10.1016/j.expneurol.2015.05.021] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 7.0] [Reference Citation Analysis]
91 Segura-Garcia C, Rania M, Carbone EA, de Filippis R, Aloi M, Caroleo M, Grasso G, Calabrò G, Fazia G, Staltari FA, Falvo A, Pugliese V, Gaetano R, Steardo L Jr, De Fazio P. Naturalistic and Uncontrolled Pilot Study on the Efficacy of Vortioxetine in Binge Eating Disorder With Comorbid Depression. Front Psychiatry 2021;12:635502. [PMID: 33815170 DOI: 10.3389/fpsyt.2021.635502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
92 Christensen MC, Florea I, Lindsten A, Baldwin DS. Efficacy of vortioxetine on the physical symptoms of major depressive disorder. J Psychopharmacol 2018;32:1086-97. [PMID: 30047820 DOI: 10.1177/0269881118788826] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
93 Witt NA, Lee B, Ghent K, Zhang WQ, Pehrson AL, Sánchez C, Gould GG. Vortioxetine Reduces Marble Burying but Only Transiently Enhances Social Interaction Preference in Adult Male BTBR T + Itpr3 tf /J Mice. ACS Chem Neurosci 2019;10:4319-27. [DOI: 10.1021/acschemneuro.9b00386] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
94 Alboni S, Benatti C, Colliva C, Radighieri G, Blom JMC, Brunello N, Tascedda F. Vortioxetine Prevents Lipopolysaccharide-Induced Memory Impairment Without Inhibiting the Initial Inflammatory Cascade. Front Pharmacol 2020;11:603979. [PMID: 33613281 DOI: 10.3389/fphar.2020.603979] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W, Reines E. The safety and tolerability of vortioxetine: Analysis of data from randomized placebo-controlled trials and open-label extension studies. J Psychopharmacol 2016;30:242-52. [PMID: 26864543 DOI: 10.1177/0269881116628440] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 12.6] [Reference Citation Analysis]
96 Bobo W, Kelliny M, Croarkin P, Moore K. Profile of vortioxetine in the treatment of major depressive disorder: an overview of the primary and secondary literature. TCRM. [DOI: 10.2147/tcrm.s55313] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
97 Lv GB, Wang TT, Zhu HL, Wang HK, Sun W, Zhao LF. Vortioxetine induces apoptosis and autophagy of gastric cancer AGS cells via the PI3K/AKT pathway. FEBS Open Bio 2020;10:2157-65. [PMID: 32750222 DOI: 10.1002/2211-5463.12944] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Mo X, Li Y, Zhu X, Li X, Zhou H, Bi X, Li J. Vortioxetine Derivatives with Amino Acid as Promoiety: Synthesis, Activity, Stability and Preliminary Pharmacokinetic Study. J Pharm Sci 2021;110:3011-9. [PMID: 33891948 DOI: 10.1016/j.xphs.2021.04.011] [Reference Citation Analysis]
99 Turan Yücel N, Kandemir Ü, Demir Özkay Ü, Can ÖD. 5-HT1A Serotonergic, α-Adrenergic and Opioidergic Receptors Mediate the Analgesic Efficacy of Vortioxetine in Mice. Molecules 2021;26:3242. [PMID: 34071269 DOI: 10.3390/molecules26113242] [Reference Citation Analysis]
100 Nierenberg A, Loft H, Olsen C. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. Journal of Affective Disorders 2019;250:35-42. [DOI: 10.1016/j.jad.2019.02.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
101 Vieta E, Sluth LB, Olsen CK. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram. J Affect Disord 2018;227:803-9. [PMID: 29673132 DOI: 10.1016/j.jad.2017.11.053] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
102 Chen F, Danladi J, Ardalan M, Nyengaard JR, Sanchez C, Wegener G. The rat hippocampal gliovascular system following one week vortioxetine and fluoxetine. Eur Neuropsychopharmacol 2021;42:45-56. [PMID: 33199100 DOI: 10.1016/j.euroneuro.2020.11.008] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): actions at serotonin receptors may enhance downstream release of four pro-cognitive neurotransmitters. CNS Spectr 2015;20:515-9. [DOI: 10.1017/s1092852915000358] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 2.2] [Reference Citation Analysis]
104 Lenze EJ, Stevens A, Waring JD, Pham VT, Haddad R, Shimony J, Miller JP, Bowie CR. Augmenting Computerized Cognitive Training With Vortioxetine for Age-Related Cognitive Decline: A Randomized Controlled Trial. Am J Psychiatry 2020;177:548-55. [PMID: 32212856 DOI: 10.1176/appi.ajp.2019.19050561] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 12.0] [Reference Citation Analysis]
105 Nissen TD, Laursen B, Viardot G, l'Hostis P, Danjou P, Sluth LB, Gram M, Bastlund JF, Christensen SR, Drewes AM. Effects of Vortioxetine and Escitalopram on Electroencephalographic Recordings – A Randomized, Crossover Trial in Healthy Males. Neuroscience 2020;424:172-81. [DOI: 10.1016/j.neuroscience.2019.09.039] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
106 Millan MJ, Goodwin GM, Hamon M, Meyer-lindenberg A, Ögren SO. 60 years of advances in neuropsychopharmacology for improving brain health, renewed hope for progress. European Neuropsychopharmacology 2015;25:591-8. [DOI: 10.1016/j.euroneuro.2015.01.015] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
107 Tiger M, Varnäs K, Okubo Y, Lundberg J. The 5-HT1B receptor - a potential target for antidepressant treatment. Psychopharmacology (Berl) 2018;235:1317-34. [PMID: 29546551 DOI: 10.1007/s00213-018-4872-1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
108 Zugliani MM, Cabo MC, Nardi AE, Perna G, Freire RC. Pharmacological and Neuromodulatory Treatments for Panic Disorder: Clinical Trials from 2010 to 2018. Psychiatry Investig 2019;16:50-8. [PMID: 30696238 DOI: 10.30773/pi.2018.12.21.1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
109 Vieta E, Florea I, Schmidt SN, Areberg J, Ettrup A. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 2-week, randomized, double-blind, placebo-controlled study. Int Clin Psychopharmacol 2019;34:153-60. [PMID: 31094901 DOI: 10.1097/YIC.0000000000000271] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
110 Yoshimura R, Ikenouchi A, Okamoto N, Konishi Y. Vortioxetine Improved Depressive State In Parkinson's Disease. Cureus 2021;13:e15750. [PMID: 34290929 DOI: 10.7759/cureus.15750] [Reference Citation Analysis]
111 Rodríguez Cerdeira C, Sánchez-Blanco E, Sánchez-Blanco B, González-Cespón JL; Working Group of IISGS. Protein biomarkers of mood disorders. Int J Immunopathol Pharmacol 2017;30:7-12. [PMID: 27903845 DOI: 10.1177/0394632016681017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
112 Massoudi B, Holvast F, Bockting CLH, Burger H, Blanker MH. The effectiveness and cost-effectiveness of e-health interventions for depression and anxiety in primary care: A systematic review and meta-analysis. J Affect Disord 2019;245:728-43. [PMID: 30447572 DOI: 10.1016/j.jad.2018.11.050] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
113 Behlke LM, Lenze EJ, Carney RM. The Cardiovascular Effects of Newer Antidepressants in Older Adults and Those With or At High Risk for Cardiovascular Diseases. CNS Drugs 2020;34:1133-47. [PMID: 33064291 DOI: 10.1007/s40263-020-00763-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
114 Gonda X, Sharma SR, Tarazi FI. Vortioxetine: a novel antidepressant for the treatment of major depressive disorder. Expert Opinion on Drug Discovery 2018;14:81-9. [DOI: 10.1080/17460441.2019.1546691] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 8.0] [Reference Citation Analysis]
115 Jacobsen P, Zhong W, Xu R, Nomikos G. A novel study design for investigating relapse prevention in major depressive disorder: Preliminary data from the open-label period of a phase 4 vortioxetine study. J Affect Disord 2020;266:173-81. [PMID: 32056873 DOI: 10.1016/j.jad.2020.01.090] [Reference Citation Analysis]
116 Al-Sukhni M, Maruschak NA, McIntyre RS. Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf 2015;14:1291-304. [PMID: 26022537 DOI: 10.1517/14740338.2015.1046836] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
117 Eap CB, Gründer G, Baumann P, Ansermot N, Conca A, Corruble E, Crettol S, Dahl ML, de Leon J, Greiner C, Howes O, Kim E, Lanzenberger R, Meyer JH, Moessner R, Mulder H, Müller DJ, Reis M, Riederer P, Ruhe HG, Spigset O, Spina E, Stegman B, Steimer W, Stingl J, Suzen S, Uchida H, Unterecker S, Vandenberghe F, Hiemke C. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants. World J Biol Psychiatry 2021;:1-68. [PMID: 33977870 DOI: 10.1080/15622975.2021.1878427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
118 Okada M, Okubo R, Fukuyama K. Vortioxetine Subchronically Activates Serotonergic Transmission via Desensitization of Serotonin 5-HT1A Receptor with 5-HT3 Receptor Inhibition in Rats. Int J Mol Sci 2019;20:E6235. [PMID: 31835640 DOI: 10.3390/ijms20246235] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
119 Hlavacova N, Li Y, Pehrson A, Sanchez C, Bermudez I, Csanova A, Jezova D, Franklin M. Effects of vortioxetine on biomarkers associated with glutamatergic activity in an SSRI insensitive model of depression in female rats. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2018;82:332-8. [DOI: 10.1016/j.pnpbp.2017.07.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
120 Caraci F, Leggio GM, Salomone S, Drago F. New drugs in psychiatry: focus on new pharmacological targets. F1000Res 2017;6:397. [PMID: 28408985 DOI: 10.12688/f1000research.10233.1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
121 Hillhouse TM, Merritt CR, Smith DA, Cajina M, Sanchez C, Porter JH, Pehrson AL. Vortioxetine Differentially Modulates MK-801-Induced Changes in Visual Signal Detection Task Performance and Locomotor Activity. Front Pharmacol 2018;9:1024. [PMID: 30271344 DOI: 10.3389/fphar.2018.01024] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
122 Pehrson AL, Pedersen CS, Tølbøl KS, Sanchez C. Vortioxetine Treatment Reverses Subchronic PCP Treatment-Induced Cognitive Impairments: A Potential Role for Serotonin Receptor-Mediated Regulation of GABA Neurotransmission. Front Pharmacol 2018;9:162. [PMID: 29559911 DOI: 10.3389/fphar.2018.00162] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
123 Rajeshkumar V, Neelamegam C, Anandan S. A one-pot metal-free protocol for the synthesis of chalcogenated furans from 1,4-enediones and thiols. Org Biomol Chem 2019;17:982-91. [DOI: 10.1039/c8ob03051k] [Cited by in Crossref: 8] [Article Influence: 4.0] [Reference Citation Analysis]
124 Ślifirski G, Król M, Turło J. 5-HT Receptors and the Development of New Antidepressants. Int J Mol Sci 2021;22:9015. [PMID: 34445721 DOI: 10.3390/ijms22169015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Robson MJ, Quinlan MA, Blakely RD. Immune System Activation and Depression: Roles of Serotonin in the Central Nervous System and Periphery. ACS Chem Neurosci 2017;8:932-42. [PMID: 28345868 DOI: 10.1021/acschemneuro.6b00412] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 10.0] [Reference Citation Analysis]
126 Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of Vortioxetine on Emotional Blunting in Patients with Major Depressive Disorder with inadequate response to SSRI/SNRI treatment. J Affect Disord 2021;283:472-9. [PMID: 33516560 DOI: 10.1016/j.jad.2020.11.106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Zheng G, Xue W, Yang F, Zhang Y, Chen Y, Yao X, Zhu F. Revealing vilazodone's binding mechanism underlying its partial agonism to the 5-HT1A receptor in the treatment of major depressive disorder. Phys Chem Chem Phys 2017;19:28885-96. [PMID: 29057413 DOI: 10.1039/c7cp05688e] [Cited by in Crossref: 28] [Cited by in F6Publishing: 13] [Article Influence: 9.3] [Reference Citation Analysis]
128 Pehrson AL, Jeyarajah T, Sanchez C. Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission. CNS Spectr 2016;21:162-83. [DOI: 10.1017/s1092852915000486] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
129 Strekowski L, Sączewski J, Raux EA, Fernando NT, Klenc J, Paranjpe S, Raszkiewicz A, Blake AL, Ehalt AJ, Barnes S, Baranowski TC, Sullivan SM, Satała G, Bojarski AJ. Synthesis and Structure-Activity Relationship Analysis of 5-HT₇ Receptor Antagonists: Piperazin-1-yl Substituted Unfused Heterobiaryls. Molecules 2016;21:433. [PMID: 27043518 DOI: 10.3390/molecules21040433] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
130 Malhi GS, Bassett D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, Hopwood M, Lyndon B, Mulder R, Murray G, Porter R, Singh AB. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry 2015;49:1087-206. [DOI: 10.1177/0004867415617657] [Cited by in Crossref: 414] [Cited by in F6Publishing: 334] [Article Influence: 69.0] [Reference Citation Analysis]
131 Ye X, Wang D, Zhu H, Wang D, Li J, Tang Y, Wu J. Gut Microbiota Changes in Patients With Major Depressive Disorder Treated With Vortioxetine. Front Psychiatry 2021;12:641491. [PMID: 34025474 DOI: 10.3389/fpsyt.2021.641491] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
132 Robbins TW. Pharmacological treatment of cognitive deficits in nondementing mental health disorders
. Dialogues Clin Neurosci 2019;21:301-8. [PMID: 31749654 DOI: 10.31887/DCNS.2019.21.3/trobbins] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 12.0] [Reference Citation Analysis]
133 Martin V, Riffaud A, Marday T, Brouillard C, Franc B, Tassin JP, Sevoz-Couche C, Mongeau R, Lanfumey L. Response of Htr3a knockout mice to antidepressant treatment and chronic stress. Br J Pharmacol 2017;174:2471-83. [PMID: 28493335 DOI: 10.1111/bph.13857] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
134 Modica MN, Intagliata S, Pittalà V, Salerno L, Siracusa MA, Cagnotto A, Salmona M, Romeo G. Synthesis and binding properties of new long-chain 4-substituted piperazine derivatives as 5-HT1A and 5-HT7 receptor ligands. Bioorganic & Medicinal Chemistry Letters 2015;25:1427-30. [DOI: 10.1016/j.bmcl.2015.02.042] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
135 Pérez PD, Ma Z, Hamilton C, Sánchez C, Mørk A, Pehrson AL, Bundgaard C, Zhang N. Acute effects of vortioxetine and duloxetine on resting-state functional connectivity in the awake rat. Neuropharmacology 2018;128:379-87. [PMID: 29104073 DOI: 10.1016/j.neuropharm.2017.10.038] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
136 Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV. The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. Brain Behav 2017;7:e00622. [PMID: 28293465 DOI: 10.1002/brb3.622] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
137 Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y, Keefe RS. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder. Neuropsychopharmacology 2015;40:2025-37. [PMID: 25687662 DOI: 10.1038/npp.2015.52] [Cited by in Crossref: 160] [Cited by in F6Publishing: 138] [Article Influence: 26.7] [Reference Citation Analysis]
138 Modica MN, Lacivita E, Intagliata S, Salerno L, Romeo G, Pittalà V, Leopoldo M. Structure-Activity Relationships and Therapeutic Potentials of 5-HT7 Receptor Ligands: An Update. J Med Chem 2018;61:8475-503. [PMID: 29767995 DOI: 10.1021/acs.jmedchem.7b01898] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
139 Waller JA, Nygaard SH, Li Y, du Jardin KG, Tamm JA, Abdourahman A, Elfving B, Pehrson AL, Sánchez C, Wernersson R. Neuroplasticity pathways and protein-interaction networks are modulated by vortioxetine in rodents. BMC Neurosci 2017;18:56. [PMID: 28778148 DOI: 10.1186/s12868-017-0376-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
140 Andersen J, Ladefoged LK, Wang D, Kristensen TN, Bang-Andersen B, Kristensen AS, Schiøtt B, Strømgaard K. Binding of the multimodal antidepressant drug vortioxetine to the human serotonin transporter. ACS Chem Neurosci 2015;6:1892-900. [PMID: 26389667 DOI: 10.1021/acschemneuro.5b00225] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
141 Micov AM, Tomić MA, Todorović MB, Vuković MJ, Pecikoza UB, Jasnic NI, Djordjevic JD, Stepanović-Petrović RM. Vortioxetine reduces pain hypersensitivity and associated depression-like behavior in mice with oxaliplatin-induced neuropathy. Prog Neuropsychopharmacol Biol Psychiatry 2020;103:109975. [PMID: 32464241 DOI: 10.1016/j.pnpbp.2020.109975] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
142 Cullen KR, Padilla LE, Papke VN, Klimes-dougan B. New Somatic Treatments for Child and Adolescent Depression. Curr Treat Options Psych 2019;6:380-400. [DOI: 10.1007/s40501-019-00194-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
143 McIntyre RS, Loft H, Christensen MC. Efficacy of Vortioxetine on Anhedonia: Results from a Pooled Analysis of Short-Term Studies in Patients with Major Depressive Disorder. Neuropsychiatr Dis Treat 2021;17:575-85. [PMID: 33654400 DOI: 10.2147/NDT.S296451] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
144 Connolly KR, Thase ME. Vortioxetine: a New Treatment for Major Depressive Disorder. Expert Opinion on Pharmacotherapy 2016;17:421-31. [DOI: 10.1517/14656566.2016.1133588] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 7.2] [Reference Citation Analysis]
145 Waller JA, Chen F, Sánchez C. Vortioxetine promotes maturation of dendritic spines in vitro: A comparative study in hippocampal cultures. Neuropharmacology 2016;103:143-54. [PMID: 26702943 DOI: 10.1016/j.neuropharm.2015.12.012] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
146 Villas Boas GR, Boerngen de Lacerda R, Paes MM, Gubert P, Almeida WLDC, Rescia VC, de Carvalho PMG, de Carvalho AAV, Oesterreich SA. Molecular aspects of depression: A review from neurobiology to treatment. Eur J Pharmacol 2019;851:99-121. [PMID: 30776369 DOI: 10.1016/j.ejphar.2019.02.024] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 13.5] [Reference Citation Analysis]
147 Smart C, McAllister-Williams H, Cousins DA. Acetylcholinesterase inhibitors in treatment-resistant psychotic depression. Ther Adv Psychopharmacol 2018;8:59-61. [PMID: 29344344 DOI: 10.1177/2045125317718810] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
148 Fakhfouri G, Rahimian R, Dyhrfjeld-Johnsen J, Zirak MR, Beaulieu JM. 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface. Pharmacol Rev 2019;71:383-412. [PMID: 31243157 DOI: 10.1124/pr.118.015487] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 14.5] [Reference Citation Analysis]
149 Kubacka M, Mogilski S, Bednarski M, Nowiński L, Dudek M, Żmudzka E, Siwek A, Waszkielewicz AM, Marona H, Satała G, Bojarski A, Filipek B, Pytka K. Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action. Pharmacol Biochem Behav 2016;141:28-41. [PMID: 26647362 DOI: 10.1016/j.pbb.2015.11.013] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
150 Liu X, Sun YX, Zhang CC, Zhang XQ, Zhang Y, Wang T, Ma YN, Wang H, Su YA, Li JT, Si TM. Vortioxetine attenuates the effects of early-life stress on depression-like behaviors and monoamine transporters in female mice. Neuropharmacology 2021;186:108468. [PMID: 33485943 DOI: 10.1016/j.neuropharm.2021.108468] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Dale E, Pehrson AL, Jeyarajah T, Li Y, Leiser SC, Smagin G, Olsen CK, Sanchez C. Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function. CNS Spectr 2016;21:143-61. [PMID: 26346726 DOI: 10.1017/S1092852915000425] [Cited by in Crossref: 65] [Cited by in F6Publishing: 32] [Article Influence: 10.8] [Reference Citation Analysis]
152 Mazza MG, Rossetti A, Botti ER, Clerici M. Vortioxetine overdose in a suicidal attempt: A case report. Medicine (Baltimore) 2018;97:e10788. [PMID: 29923970 DOI: 10.1097/MD.0000000000010788] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
153 Newman-tancredi A, Depoortère R, Carilla-durand E, Tarayre J, Kleven M, Koek W, Bardin L, Varney M. NLX-112, a highly selective 5-HT1A receptor agonist: Effects on body temperature and plasma corticosterone levels in rats. Pharmacology Biochemistry and Behavior 2018;165:56-62. [DOI: 10.1016/j.pbb.2017.11.002] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
154 Ślifirski G, Król M, Kleps J, Podsadni P, Belka M, Bączek T, Siwek A, Stachowicz K, Szewczyk B, Nowak G, Bojarski A, Kozioł AE, Turło J, Herold F. Synthesis of new 5,6,7,8-tetrahydropyrido[1,2-c]pyrimidine derivatives with rigidized tryptamine moiety as potential SSRI and 5-HT1A receptor ligands. Eur J Med Chem 2019;180:383-97. [PMID: 31325785 DOI: 10.1016/j.ejmech.2019.07.027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
155 Kugathasan P, Waller J, Westrich L, Abdourahman A, Tamm JA, Pehrson AL, Dale E, Gulinello M, Sanchez C, Li Y. In vivo and in vitro effects of vortioxetine on molecules associated with neuroplasticity. J Psychopharmacol 2017;31:365-76. [PMID: 27678087 DOI: 10.1177/0269881116667710] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
156 Dale E, Bang-andersen B, Sánchez C. Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs. Biochemical Pharmacology 2015;95:81-97. [DOI: 10.1016/j.bcp.2015.03.011] [Cited by in Crossref: 123] [Cited by in F6Publishing: 113] [Article Influence: 20.5] [Reference Citation Analysis]
157 Schwasinger-schmidt TE, Macaluso M. Other Antidepressants. In: Macaluso M, Preskorn SH, editors. Antidepressants. Cham: Springer International Publishing; 2019. pp. 325-55. [DOI: 10.1007/164_2018_167] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
158 Dale E, Grunnet M, Pehrson AL, Frederiksen K, Larsen PH, Nielsen J, Stensbøl TB, Ebert B, Yin H, Lu D, Liu H, Jensen TN, Yang CR, Sanchez C. The multimodal antidepressant vortioxetine may facilitate pyramidal cell firing by inhibition of 5-HT3 receptor expressing interneurons: An in vitro study in rat hippocampus slices. Brain Res 2018;1689:1-11. [PMID: 29274875 DOI: 10.1016/j.brainres.2017.12.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
159 Sharp AM, Lertphinyowong S, Yee SS, Paredes D, Gelfond J, Johnson-Pais TL, Leach RJ, Liss M, Risinger AL, Sullivan AC, Thompson IM, Morilak DA. Vortioxetine reverses medial prefrontal cortex-mediated cognitive deficits in male rats induced by castration as a model of androgen deprivation therapy for prostate cancer. Psychopharmacology (Berl) 2019;236:3183-95. [PMID: 31139875 DOI: 10.1007/s00213-019-05274-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
160 Kall MA, Rohde M, Jørgensen M. Quantitative determination of the antidepressant vortioxetine and its major human metabolite in plasma. Bioanalysis 2015;7:2881-94. [DOI: 10.4155/bio.15.207] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
161 Staroń J, Bugno R, Hogendorf AS, Bojarski AJ. 5-HT1A receptor ligands and their therapeutic applications: review of new patents. Expert Opinion on Therapeutic Patents 2018;28:679-89. [DOI: 10.1080/13543776.2018.1514011] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
162 Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SCR, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H, Roberts A, Roth BL, Roumier A, Sanger GJ, Teitler M, Sharp T, Villalón CM, Vogel H, Watts SW, Hoyer D. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol Rev 2021;73:310-520. [PMID: 33370241 DOI: 10.1124/pr.118.015552] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 25.0] [Reference Citation Analysis]
163 Emam AM, Saad MA, Ahmed NA, Zaki HF. Vortioxetine mitigates neuronal damage by restricting PERK/eIF2α/ATF4/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion. Life Sci 2021;283:119865. [PMID: 34358549 DOI: 10.1016/j.lfs.2021.119865] [Reference Citation Analysis]
164 Perez-Caballero L, Torres-Sanchez S, Romero-López-Alberca C, González-Saiz F, Mico JA, Berrocoso E. Monoaminergic system and depression. Cell Tissue Res 2019;377:107-13. [PMID: 30627806 DOI: 10.1007/s00441-018-2978-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 14.0] [Reference Citation Analysis]
165 Wang L, Zhang Y, Du X, Ding T, Gong W, Liu F. Review of antidepressants in clinic and active ingredients of traditional Chinese medicine targeting 5-HT1A receptors. Biomedicine & Pharmacotherapy 2019;120:109408. [DOI: 10.1016/j.biopha.2019.109408] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
166 Khoury R, Grossberg GT. Impact of Antidepressant Use on the Trajectory of Alzheimer's Disease: Evidence, Mechanisms, and Therapeutic Implications. CNS Drugs 2019;33:17-29. [PMID: 30456746 DOI: 10.1007/s40263-018-0590-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
167 Hjorth S. Looking back (and in)to the future: A personal reflection on ‘Serotonin autoreceptor function and antidepressant drug action’ (Hjorth et al., 2000). J Psychopharmacol 2016;30:1129-36. [DOI: 10.1177/0269881116647621] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
168 Christensen MC, Fagiolini A, Florea I, Loft H, Cuomo A, Goodwin GM. Validation of the Oxford Depression Questionnaire: Sensitivity to change, minimal clinically important difference, and response threshold for the assessment of emotional blunting. J Affect Disord 2021;294:924-31. [PMID: 34378539 DOI: 10.1016/j.jad.2021.07.099] [Reference Citation Analysis]
169 Chen G, Højer AM, Areberg J, Nomikos G. Vortioxetine: Clinical Pharmacokinetics and Drug Interactions. Clin Pharmacokinet 2018;57:673-86. [PMID: 29189941 DOI: 10.1007/s40262-017-0612-7] [Cited by in Crossref: 40] [Cited by in F6Publishing: 25] [Article Influence: 20.0] [Reference Citation Analysis]
170 Juza R, Vlcek P, Mezeiova E, Musilek K, Soukup O, Korabecny J. Recent advances with 5-HT3 modulators for neuropsychiatric and gastrointestinal disorders. Med Res Rev 2020;40:1593-678. [PMID: 32115745 DOI: 10.1002/med.21666] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
171 Okada M, Matsumoto R, Yamamoto Y, Fukuyama K. Effects of Subchronic Administrations of Vortioxetine, Lurasidone, and Escitalopram on Thalamocortical Glutamatergic Transmission Associated with Serotonin 5-HT7 Receptor. Int J Mol Sci 2021;22:1351. [PMID: 33572981 DOI: 10.3390/ijms22031351] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
172 Andreetta F, Carboni L, Grafton G, Jeggo R, Whyment AD, van den Top M, Hoyer D, Spanswick D, Barnes NM. Hippocampal 5-HT7 receptors signal phosphorylation of the GluA1 subunit to facilitate AMPA receptor mediated-neurotransmission in vitro and in vivo. Br J Pharmacol 2016;173:1438-51. [PMID: 26773257 DOI: 10.1111/bph.13432] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
173 Gupta D, Prabhakar V, Radhakrishnan M. 5HT3 receptors: Target for new antidepressant drugs. Neurosci Biobehav Rev 2016;64:311-25. [PMID: 26976353 DOI: 10.1016/j.neubiorev.2016.03.001] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
174 Dunlop BW, Rakofsky JJ, Newport DJ, Mletzko-Crowe T, Barone K, Nemeroff CB, Harvey PD. Efficacy of Vortioxetine Monotherapy for Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial. J Clin Psychopharmacol 2021;41:172-9. [PMID: 33587394 DOI: 10.1097/JCP.0000000000001363] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Xue W, Fu T, Zheng G, Tu G, Zhang Y, Yang F, Tao L, Yao L, Zhu F. Recent Advances and Challenges of the Drugs Acting on Monoamine Transporters. CMC 2020;27:3830-76. [DOI: 10.2174/0929867325666181009123218] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
176 Millan MJ, Rivet J, Gobert A. The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders. J Psychopharmacol 2016;30:1099-128. [DOI: 10.1177/0269881116672342] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
177 Grosso C. Future Strategies for the Treatment of Depression. In: Grosso C, editor. Herbal Medicine in Depression. Cham: Springer International Publishing; 2016. pp. 557-71. [DOI: 10.1007/978-3-319-14021-6_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
178 Liu FG, Hu WF, Wang JL, Wang P, Gong Y, Tong LJ, Jiang B, Zhang W, Qin YB, Chen Z, Yang RR, Huang C. Z-Guggulsterone Produces Antidepressant-Like Effects in Mice through Activation of the BDNF Signaling Pathway. Int J Neuropsychopharmacol 2017;20:485-97. [PMID: 28339691 DOI: 10.1093/ijnp/pyx009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 5.3] [Reference Citation Analysis]
179 Chen F, Danladi J, Ardalan M, Elfving B, Müller HK, Wegener G, Sanchez C, Nyengaard JR. A Critical Role of Mitochondria in BDNF-Associated Synaptic Plasticity After One-Week Vortioxetine Treatment. Int J Neuropsychopharmacol 2018;21:603-15. [PMID: 29514282 DOI: 10.1093/ijnp/pyy022] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
180 Jacobson W, Zhong W, Nomikos GG, Christensen MC, Kurre Olsen C, Harvey PD. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis. Current Medical Research and Opinion 2020;36:117-24. [DOI: 10.1080/03007995.2019.1657692] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
181 Leiser SC, Li Y, Pehrson AL, Dale E, Smagin G, Sanchez C. Serotonergic Regulation of Prefrontal Cortical Circuitries Involved in Cognitive Processing: A Review of Individual 5-HT Receptor Mechanisms and Concerted Effects of 5-HT Receptors Exemplified by the Multimodal Antidepressant Vortioxetine. ACS Chem Neurosci 2015;6:970-86. [DOI: 10.1021/cn500340j] [Cited by in Crossref: 68] [Cited by in F6Publishing: 64] [Article Influence: 11.3] [Reference Citation Analysis]
182 Sharp T, Barnes NM. Central 5-HT receptors and their function; present and future. Neuropharmacology 2020;177:108155. [PMID: 32522572 DOI: 10.1016/j.neuropharm.2020.108155] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 21.0] [Reference Citation Analysis]
183 Heal DJ, Smith SL. Prospects for new drugs to treat binge-eating disorder: Insights from psychopathology and neuropharmacology. J Psychopharmacol 2021;:2698811211032475. [PMID: 34318734 DOI: 10.1177/02698811211032475] [Reference Citation Analysis]
184 He S, Zhang X, Zhang S, Guan S, Li J, Li S, Zhang L. An Investigation Into Vortioxetine Salts: Crystal Structure, Thermal Stability, and Solubilization. Journal of Pharmaceutical Sciences 2016;105:2123-8. [DOI: 10.1016/j.xphs.2016.04.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
185 Jiang LX, Huang GD, Su F, Wang H, Zhang C, Yu X. Vortioxetine administration attenuates cognitive and synaptic deficits in 5×FAD mice. Psychopharmacology (Berl) 2020;237:1233-43. [PMID: 31953648 DOI: 10.1007/s00213-020-05452-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
186 Stahl SM. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): modifying serotonin's downstream effects on glutamate and GABA (gamma amino butyric acid) release. CNS Spectr 2015;20:331-6. [PMID: 26062900 DOI: 10.1017/S1092852915000334] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
187 Keefe RSE, Nomikos G, Zhong W, Christensen MC, Jacobson W. A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction. Int J Neuropsychopharmacol 2018;21:442-7. [PMID: 29546401 DOI: 10.1093/ijnp/pyy020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
188 Wróbel MZ, Chodkowski A, Herold F, Marciniak M, Dawidowski M, Siwek A, Starowicz G, Stachowicz K, Szewczyk B, Nowak G, Belka M, Bączek T, Satała G, Bojarski AJ, Turło J. Synthesis and biological evaluation of new multi-target 3-(1H-indol-3-yl)pyrrolidine-2,5-dione derivatives with potential antidepressant effect. European Journal of Medicinal Chemistry 2019;183:111736. [DOI: 10.1016/j.ejmech.2019.111736] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
189 Reyes-parada M, Iturriaga-vasquez P. The development of novel polypharmacological agents targeting the multiple binding sites of nicotinic acetylcholine receptors. Expert Opinion on Drug Discovery 2016;11:969-81. [DOI: 10.1080/17460441.2016.1227317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
190 Li G, Wang X, Ma D. The efficacy and safety of 10 mg vortioxetine in the treatment of major depressive disorder: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat 2016;12:523-31. [PMID: 27013879 DOI: 10.2147/NDT.S103173] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
191 Chen F, du Jardin KG, Waller JA, Sanchez C, Nyengaard JR, Wegener G. Vortioxetine promotes early changes in dendritic morphology compared to fluoxetine in rat hippocampus. Eur Neuropsychopharmacol 2016;26:234-45. [PMID: 26711685 DOI: 10.1016/j.euroneuro.2015.12.018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
192 Florea I, Danchenko N, Brignone M, Loft H, Rive B, Abetz-webb L. The Effect of Vortioxetine on Health-related Quality of Life in Patients With Major Depressive Disorder. Clinical Therapeutics 2015;37:2309-2323.e6. [DOI: 10.1016/j.clinthera.2015.08.008] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
193 Sagud M, Nikolac Perkovic M, Vuksan-cusa B, Maravic A, Svob Strac D, Mihaljevic Peles A, Zivkovic M, Kusevic Z, Pivac N. A prospective, longitudinal study of platelet serotonin and plasma brain-derived neurotrophic factor concentrations in major depression: effects of vortioxetine treatment. Psychopharmacology 2016;233:3259-67. [DOI: 10.1007/s00213-016-4364-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
194 Chokka P, Tvistholm AH, Bougie J, Clerzius G, Ettrup A. Improvements in Workplace Productivity in Working Patients With Major Depressive Disorder: Results From the AtWoRC Study. J Occup Environ Med 2020;62:e94-e101. [PMID: 31895735 DOI: 10.1097/JOM.0000000000001805] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
195 Chin CN, Zain A, Hemrungrojn S, Ung EK, Kwansanit P, Au Yong KC, Chong MSW, Inpa C, Yen TH, Yeoh BBD, Tay LK, Bernardo C, Lim LC, Yap CH, Fones C, Nayak A, Nelleman L. Results of a real-world study on vortioxetine in patients with major depressive disorder in South East Asia (REVIDA). Curr Med Res Opin 2018;34:1975-84. [PMID: 29768955 DOI: 10.1080/03007995.2018.1477746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
196 Chokka P, Bougie J, Proulx J, Tvistholm AH, Ettrup A. Long-term functioning outcomes are predicted by cognitive symptoms in working patients with major depressive disorder treated with vortioxetine: results from the AtWoRC study. CNS Spectr 2019;24:616-27. [PMID: 30802419 DOI: 10.1017/S1092852919000786] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
197 Artigas F, Bortolozzi A, Celada P. Can we increase speed and efficacy of antidepressant treatments? Part I: General aspects and monoamine-based strategies. Eur Neuropsychopharmacol 2018;28:445-56. [PMID: 29174531 DOI: 10.1016/j.euroneuro.2017.10.032] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 10.8] [Reference Citation Analysis]
198 Lu Y, Ho CS, McIntyre RS, Wang W, Ho RC. Effects of vortioxetine and fluoxetine on the level of Brain Derived Neurotrophic Factors (BDNF) in the hippocampus of chronic unpredictable mild stress-induced depressive rats. Brain Res Bull 2018;142:1-7. [PMID: 29933036 DOI: 10.1016/j.brainresbull.2018.06.007] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 13.0] [Reference Citation Analysis]
199 Arnaud A, Suthoff E, Stenson K, Werneburg B, Hodgkins P, Bonthapally V, Jonas J, Meyer K, O'Day K. Number Needed to Treat and Number Needed to Harm analysis of the zuranolone phase 2 clinical trial results in major depressive disorder. J Affect Disord 2021;285:112-9. [PMID: 33640861 DOI: 10.1016/j.jad.2021.02.027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Han YX, Tao C, Gao XR, Wang LL, Jiang FH, Wang C, Fang K, Chen XX, Chen Z, Ge JF. BDNF-Related Imbalance of Copine 6 and Synaptic Plasticity Markers Couples With Depression-Like Behavior and Immune Activation in CUMS Rats. Front Neurosci 2018;12:731. [PMID: 30429764 DOI: 10.3389/fnins.2018.00731] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
201 Ladefoged LK, Munro L, Pedersen AJ, Lummis SCR, Bang-andersen B, Balle T, Schiøtt B, Kristensen AS. Modeling and Mutational Analysis of the Binding Mode for the Multimodal Antidepressant Drug Vortioxetine to the Human 5-HT 3A Receptor. Mol Pharmacol 2018;94:1421-34. [DOI: 10.1124/mol.118.113530] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]